Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer

Dr. D'Amico challenges panel of experts with tough prostate cancer Case Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer (INTERACTIVE) EDU 06

Date: 9/24/2017 Time: 4:45 p.m. - 6:15 p.m.

Location: San Diego Convention Center

Chair: Anthony DAmico, MD, PhD, FASTRO Brigham And Women's Hospital Professor, Radiation Oncology, Harvard Medical School Chief, Genitourinary Radiation Oncology, Brigham And Women's Hospital Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute DF/HCC PROGRAM AFFILIATION Prostate Cancer, Member Research - My research is focused on two levels. At the basic science level, I have independent funding to support work in two laboratories. One lab is investigating the effect that benign prostatic epithelial and stromal cells have on the growth of juxtaposed malignant prostatic epithelial cells. This work aims to explain an improved PSA failure survival that I noted in prostate cancer patients managed with RT or surgery who also had moderate benign prostatic hypertrophy. The second lab is dedicated to the synthesis of prostate specific antigen cleavable pro-drugs whose target is the androgen independent metastatic prostate cancer cell. On the clinical research level, I am the principal investigator of a national phase II prospective trial which will determine ability of endorectal coil MRI to assess androgen responsiveness and outcome (cause-specific and overall survival) after external beam radiation therapy and androgen suppression therapy for prostate cancer. I am also the principal investigator of a phase III prospective randomized trial evaluating the impact on survival (cause-specific and overall) from the addition of androgen suppression therapy to external beam radiation therapy for localized prostate cancer. I have developed a staging system for clinically localized prostate cancer from retrospective data analysis of radiation and surgically managed patients and with others I am prospectively attempting to validate it. Other retrospective studies that I am leading include identification of the optimal patients for interstitial prostate brachytherapy, external beam plus interstitial prostate brachytherapy, and androgen suppression plus external beam and interstitial prostate brachytherapy. These studies will be the basis for patient selection for prospective trials assessing the relative efficacy of these treatments on cause-specific and overall survival. Speakers: Alan Pollack, MD, PhD Biography - Dr. Pollack is Professor and Chair of the Department of Radiation Oncology at Miller School of Medicine. He obtained a Ph.D. in Microbiology and Immunology from the University of Miami and after 5 years of translational research matriculated at the University of Miami Miller School of Medicine in the Ph.D. to M.D. program. After graduating, he did an internship in internal medicine at Jackson Memorial Hospital before doing a residency in radiation oncology at M.D. Anderson Cancer Center in Houston. While at M.D. Anderson, Dr. Pollack attained the rank of Professor, was Director of the Residency Training Program and was a co-leader of the GU group before assuming the Chair in Radiation Oncology Position at Fox Chase Cancer Center in Philadelphia in 2001. He held that position for 7 years before returning to Miami in his current position as Chair and Professor of Radiation Oncology in 2008 Research Interests  - Dr. Pollack’s research interests have centered on the management of prostate cancer with radiotherapy (RT), with and without androgen deprivation therapy (ADT). An emphasis has been placed on dose escalation, fractionation, length of ADT, tissue and imaging markers of outcome and small molecule/gene/viral vector targeted therapy.  Dr. Pollack’s quantitative imaging research on men with prostate cancer who are candidates for active surveillance is funded by the NCI. He co-leads the genitourinary translational research program in the NRG cooperative group and has published a series of papers on biomarkers that predict response to RT ± ADT for men treated on cooperative group trials. Many of these biomarkers are potential treatment targets and some of these targets have been investigated by Dr. Pollack Dr. Pollack has been the lead principal investigator on several clinical trials, including an ongoing Sylvester investigator-initiated trial of MRI-guided radiotherapy (BLaStM) and a national RTOG/NRG study (SPPORT, 0534) that has reached the accrual goal. Thomas Wiegel, MD Biography - since 2005 Head of Department fo Radiation Oncology, University Hospital Ulm/Germany; 1998 – 2004 Assistant Professor and Vice Director, Department of Radiation Oncology, Charité –Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin/Germany; 1994 – 2005 Fellow, Department of Radiation Oncology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin/Germany; 1991 – 1994 Fellow, Department of Radiation Oncology, University Hospital Hamburg/Germany; 1989 – 1991 Resident, Department of Radiation Oncology, University Hospital Hamburg/Germany  Research -  The “Prostate Cancer Outcomes” project aims to contribute to improving the physical and mental health of men being treated for localised prostate cancer. The intention of this global project is to systematically measure and (anonymously) compare clinical and patient-reported endpoints (what are known as Patient Reported Outcomes – PROs) for localised prostate cancer in clinics from several countries. In this context all participating clinics use, in a prospective manner, a standardised data set to measure patient-reported endpoints, which contains EPIC 26, an internationally established questionnaire for the measurement of health-related quality of life. Furthermore, other variables are measured which have the potential to influence these endpoints (e.g. pre- and post-therapeutic treatment regimens, work in multidisciplinary teams, etc.) Almost all these variables are already fully reported by the centres for the audits in conjunction with DKG certification. Based on these data the different results are to be analysed and characteristics identified for the best possible care. Besides the exchange of knowledge between the participating centres, the project likewise aims to disseminate knowledge beyond this circle. Christopher J. Kane, MD Chair, Department of Urology, Professor of Urology, UC San Diego  Biography - Prior to joining UC San Diego Health, Dr. Kane held leadership positions at UC San Francisco and the Naval Medical Center San Diego. He was awarded the Distinguished Engineering Alumni Medal by UC Davis in 2011. In 2014 he was elected to membership in the American Association of Genitourinary Surgeons. He is a retired Navy Captain and a decorated veteran of Desert Storm.  Dr. Kane completed his residency at the Naval Medical Center in Oakland, California. He received his medical degree from Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Kane is board-certified in urology.  Clinical Practice - Christopher J. Kane, MD, is a board-certified urologic oncologist. He has a special interest in treating patients with prostate cancer and has extensive expertise in robotic prostatectomy, open and laparoscopic kidney cancer surgery, and bladder and testes cancer surgery. Dr. Kane performs over 200 robotic cancer surgeries per year and is highly experienced in nerve sparing robotic prostatectomies, robotic radical cystectomy for bladder cancer, and robotic partial nephrectomy for kidney cancer.  Research - He is internationally recognized for patient care and research in prostate cancer, renal cell carcinoma, robotic and minimally invasive surgical treatment of urologic diseases and disorders, and risk stratification and outcomes after treatment. Dr. Kane has authored more than 240 peer-reviewed research articles with a focus on prostate cancer risk factors and outcomes, prostate cancer surgery and minimally invasive surgery for prostate and kidney cancer. He serves on the editorial boards of several major urology journals as well as the National Comprehensive Cancer Network (NCCN) Prostate Cancer Management Guidelines Committee. He also co-chairs the National Cancer Institute’s Renal Cell Carcinoma Advisory Task Force. Juanita Crook, MD Biography -Dr. Juanita Crook | BC Cancer Foundation Dr. Crook is a Professor of Radiation Oncology at the University of British Columbia and on staff at the Cancer Centre for the Southern Interior in Kelowna, B.C. She is a recognized expert in the field of brachytherapy for prostate cancer and penile cancer.  Research - Her research has included predictive factors for post implant toxicity, guidelines for the reporting of critical organ doses following brachytherapy and she has led the way in the use of MRI-CT fusion for quality assurance of prostate brachytherapy. She has written 23 book chapters, over 150 journal articles and is a frequent speaker at international meetings, in English, French and Spanish. She was Scientific Chair of the 2007 American Brachytherapy Society (ABS) meeting, regularly teaches at the ABS Prostate Brachytherapy School and is past president and chairman of the Board of the ABS.

Objectives: After this session, attendees should be able to: Apply the randomized data regarding dose escalation and hormonal therapy to the management of men with newly diagnosed localized prostate cancer. Apply the available data on the management of a rising PSA following primary surgery or radiation therapy.

DESCRIPTION: The specific scenarios included 3 case histories of men with newly diagnosed localized, locally advanced, post-operative pT3,4 and/or margin + disease in the setting of an undetectable PSA in addition to post-operative or post-radiation PSA recurrence. An audience interactive format was used to enhance learning and provide an opportunity to ask additional questions. Initial Case Recurrence Case Recurrence Case

NASA Facts - Altair

NASA Facts - Altair FS-073.pdf

MultiDop: multi - Doppler radar analysis suite

MultiDop: An open - source, Python - powered, multi - Doppler radar analysis suite

Abstract: Toward an Open-Source, Python-Powered, Multi-Doppler Radar Analysis Suite (97th American Meteorological Society Annual Meeting)

NASA Technical Reports Server (NTRS) - MultiDop: An Open-Source, Python-Powered, Multi-Doppler Radar Analysis Suite

Severe weather research often is facilitated by multi-Doppler radar syntheses to retrieve three-dimensional winds. While numerous techniques and software packages to perform these analyses have been developed over the years [e.g.,

• GAMIC Weather Radar Software Suite - FROG MURAN, 
• A Multiple-Doppler Radar Analysis of a Three-Dimensional Wind Field -https://ams.confex.com/ams/pdfpapers/123690.pdf by J Gao - Doppler radar data assimilation for 4-node CASA radars, together with ... CAPS, Suite 2500, NWC, 120 David L. Boren Blvd,. Norman OK

to date none has been fully integrated within the Python software framework that has been growing in popularity within the weather radar science community.

This presentation discussed work that has been done to merge the three-dimensional variational analysis (3DVAR) approach developed at the University of Oklahoma with the Python Atmospheric Radiation Measurement Radar Toolkit (Py-ART) developed at Argonne National Laboratory. National Aeronautics and Space Administration (NASA) Marshall Space Flight Center (MSFC) has successfully produced a working Python-based prototype that is being released to the community at large.

The package, called MultiDop, is fully compatible with Py-ART but also takes advantage of the computational efficiency supplied by the original 3DVAR codebase. Example workflows will be described using Jupyter notebooks that ingest native spherical coordinate radar volumes, provide quality control, and then merge the data onto a common Cartesian grid and perform multiple-Doppler syntheses, with final products matching the Py-ART data model. Performance against other multi-Doppler packages (e.g., Custom Editing and Display of Reduced Information in Cartesian Space, or CEDRIC) [Reference Manual | Earth Observing Laboratory] will be assessed. The MultiDop package is intended for community use and community-directed future development via the NASA GitHub portal. MultiDop is a Python-based interface between the

C-based DDA code developed at University of Oklahoma [CIMMS: Corey Potvin] and

the Python Atmospheric Radiation Measurement Radar Toolkit (Py-ART) software developed at Argonne National Lab [pyart/advection.py at master · ARM-DOE/pyart · GitHub]. Use this software to perform 3D wind analyses using 2-3 independent Doppler radars.

Checkout of Multidop

MultiDop is available at GitHub - nasa/MultiDop: Multiple-Doppler Radar Analysis Toolkit (MultiDop)

https://github.com/nasa/MultiDop


Current version = 0.3, tested and working under Python 2.7 and 3.6 Also requires numpy, Py-ART, xarray, C compilers, and netCDF libraries
If you use MultiDop, you MUST cite the following papers:

• Shapiro, A., C. Potvin, and J. Gao, 2009: Use of a Vertical Vorticity Equation in Variational Dual-Doppler Wind Analysis. J. Atmos. Oceanic Technol., 26, 2089–2106,
  doi: https://doi.org/10.1175/2009JTECHA1256.1 or
  http://journals.ametsoc.org/doi/abs/10.1175/2009JTECHA1256.1
• Potvin, C., A. Shapiro, and M. Xue, 2012: Impact of a Vertical Vorticity Constraint in Variational Dual-Doppler Wind Analysis: Tests with Real and Simulated Supercell Data. J. Atmos. Oceanic Technol., 29, 32–49,
  http://journals.ametsoc.org/doi/abs/10.1175/JTECH-D-11-00019.1
  https://doi.org/10.1175/JTECH-D-11-00019.1

2017 Annual Meeting- American Society for Radiation Oncology (ASTRO)

2017 Annual Meeting- American Society for Radiation Oncology (ASTRO)

September 24 – 27, 2017
San Diego Convention Center

The ASTRO Annual Meeting is the world's most important meeting for the radiation oncology community, with more than 11,000 people attending each year. Learn more about what to expect at the upcoming Annual Meeting in our Annual Meeting highlights video.

Program

• Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer deaths worldwide are projected to continue to rise to more than 11 million in 2030. The American Cancer Society estimates that in 2017, 1.685 million new cases of cancer will be diagnosed. Nearly two-thirds of these patients will receive radiation therapy during their illness – most with the intent to cure the cancer. Advances in the applications, technologies and methodologies of radiation oncology continue to evolve rapidly and the delivery of radiation therapy has become more complex, making it imperative that the radiation oncology professional remain current in the state-of-the-art techniques. ASTRO is committed to providing educational programming that creates a forum for global collaboration on issues in radiation oncology to improve professional practice by increasing their level of knowledge, as required to improve competency and performance in the field of oncology.

• Program Objectives

  At the conclusion of this activity, the learner will be able to:
  

  • Examine the advances in radiation oncology technology that help improve patient outcomes and quality of life.
  • Employ quality and safety measures in the delivery of radiation therapy. 
  • Demonstrate the value of radiation oncology to patients, referring physicians and the public.

 Sessions of Interest on Prostate Cancer:

• Altering the Natural History of Oligometastatic Prostate Cancer: "Reality vs. Illusion"
  EDU 49 
• GU 3 - Emerging Outcomes for Aggressive Prostate Cancers Treated with Upfront Radiotherapy SS 38 
• ASTRO'S 2017 Annual Meeting - Image Guided Prostate Brachytherapy: Combining Science and Art to Optimize Outcomes EDU 33 
• ASTRO'S 2017 Annual Meeting - GU 1 - Genomics, Imaging and Salvage Local Therapies after Prostatectomy or Post-radiotherapy Relapse SS 28 
• ASTRO'S 2017 Annual Meeting - Optimizing Post-Prostatectomy Radiotherapy: A Multi-Disciplinary Perspective EDU 20 (Live SA-CME) 
• ASTRO'S 2017 Annual Meeting - Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer (INTERACTIVE) EDU 06

SanDiego Informed Prostate Cancer Support Group Next Meeting

San Diego Informed Prostate Cancer Support Group Next Meeting

September 16 - ADVANCES IN RADIATION THERAPY

Brent Rose, MD

Assistant Professor Radiation Oncology University of California San Diego.

Brent Rose, MD, is a radiation oncologist who specializes in treating prostate cancer, head and neck cancer, skin cancer, brain metastases and primary brain tumors. As a radiation oncologist, Dr. Rose uses carefully targeted, high doses of radiation energy to destroy or damage cancer cells. His expertise includes conformal radiation therapy (CRT), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and high-dose rate (HDR) and low-dose rate (LDR) brachytherapy.

As an assistant professor in the Department of Radiation Medicine and Applied Sciences, Dr. Rose instructs medical students, residents and fellows at UC San Diego School of Medicine.

Dr. Rose is a dedicated clinical researcher who has published over 30 journal articles and textbook chapters. His interest include developing advanced imaging and treatment techniques to improve the efficacy and reduce the side effects of cancer treatments as well as studying health outcomes data to better understand the risk and benefits of treatment and enhance shared decision making with patients and their doctors. 

He is a member of several organizations, including the American Board of Radiology and the American Society for Therapeutic Radiology and Oncology.

A native of Southern California, Dr. Rose completed his undergraduate degree (B.S. in Biology) and Medical School (M.D.) at the University of California San Diego (UCSD). Following Medical School, he moved to Boston where he completed his internship in Internal Medicine at the Beth Israel Deaconess Medical Center and Radiation Oncology Residency at the Harvard Radiation Oncology Program.

After residency, Dr. Rose joined the UCSD Radiation Medicine and Applied Sciences faculty as an Assistant Professor where he specializes in advanced radiotherapy techniques for the treatment of genitourinary, central nervous system and head and neck cancers. 

Dr. Rose’s wife, Olga, is a pediatrician and they have a young son named Erik

Recent Publications:

• Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice? - International Journal of Radiation Oncology • Biology • Physics
• Irradiation of FDG-PET Defined-Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation - International Journal of Radiation Oncology • Biology • Physics
• Prostate Cancer - Clinical Radiation Oncology: Indications, Techniques, and Results - Solanki - Wiley Online Library
• Utilization of Advanced Imaging Technologies for Target Delineation in Radiation Oncology - Journal of the American College of Radiology
• Toxicity Analysis of Postoperative Image-Guided Intensity-Modulated Radiotherapy for Prostate Cancer - ScienceDirect

GA-ASI Opens New Hangar for Grand Sky UAV Flight Test and Training Center

GA-ASI’S Flight Test and Training Center Opens New Hangar - UAS VISION

New Hangar Opens for GA-ASI's Flight Test and Training Center
Ribbon-Cutting Event Marks Completion of Permanent Hangar Facility in N.D.

GRAND FORKS – 22 August 2017 – General Atomics Aeronautical Systems, Inc. (GA-ASI) held a grand opening event yesterday for its new hangar at the Grand Sky Unmanned Aircraft System (UAS) Business Park near Grand Forks, North Dakota. The event included a ribbon-cutting ceremony to commemorate the completion of GA-ASI's new Flight Test and Training Center (FTTC) hangar.

The hangar replaces the temporary facility that has been in operation since June 2016. It will house GA-ASI operational hardware, including Remotely Piloted Aircraft (RPA) and Ground Control Stations (GCS), as well as offices and conference rooms.

"We're excited to open this new permanent hangar for our Flight Test and Training Center in North Dakota," said David R. Alexander, president, Aircraft Systems, GA-ASI. "It represents our investment in test and training capabilities, which will provide our customers with an excellent facility to train aircrews to fly our aircraft."

In addition to Mr. Alexander, Grand Opening festivities included remarks from U.S. Senator John Hoeven (R-ND); North Dakota Lieutenant Governor Brent Sanford; Field Representative Matthew Leiphon (U.S. Senator Heidi Heitkamp, D-ND); District Representative Randy Richards (U.S. Representative Kevin Cramer, R-ND); and GA-ASI Chief Executive Officer Linden Blue.

"As our UAS industry continues developing new applications for this technology in both the public and private sectors, it is vital that we have qualified operators for these aircraft," Hoeven said. "General Atomics' new training hangar is an international asset. UAS pilots from around the world will train right here in Grand Forks, further cementing our state's position as a leader in UAS research, training and operations."

The new hangar will house three GA-ASI owned RPA – a MQ-1 Predator® A and two MQ-9 Predator Bs/ (Block 1 and Block 5) – and two GCS (a Block 15 and Block 30 Mobile GCS). GA-ASI's FTTC operation also includes an office building located near the University of North Dakota campus that contains classrooms and a Predator Mission Aircrew Training System for accomplishing the academic and simulator segments of training.

"Grand Sky's goal is to create the operations-friendly environment tenants need to expand their capabilities as the UAS industry grows," said Thomas Swoyer Jr., president of Grand Sky Development Company. "From being the first to fly large UAS at the park to being the first to expand their operations, GA-ASI continues to operate at the leading edge of the industry. We're proud to count them as a partner for many years to come."

 

Related/Background:

• Industry and Company News | Grand Sky 
• GA-ASI Conducts UAS Training Academy First Flight - UAS VISION 
• Our opinion: Grand Sky gives hope for a bright 2017 | Grand Forks Herald 
• Grand Sky Drone Park – Grand Forks, North Dakota | Atlas Obscura 
• TOM SWOYER: Grand future for Grand Sky UAS business | Grand Forks Herald

• spendergast: GA-ASI and NGC plan UAS training in North Dakota 
• spendergast: GA-ASI RSG's Blue talks training facility in Grand Sky North Dakota
• General Atomics signs lease for Grand Forks drone tech park - Washington Times
• Grand Forks Will Train Predator Pilots From Around The World 
• spendergast: UAS Summit next week in Grand Forks, ND 

x

#ProstateCancer News - 2017 -09 September

Prostate Cancer News - 2017-09

General News

About prostate cancer research, cases and public awareness:

• Prostate Health Month - Prostate Health Guide
• Sanford Burnham Prebys looks to the future - The San Diego Union-Tribune
• Prostate cancer: Study identifies earlier clinical trial endpoint that can be used to indicate effectiveness of new treatments
• spendergast: September is Prostate Cancer Awareness Month  
• CDC - Prostate Cancer Awareness Feature

Case Management

Planning a campaign against prostate cancer:

• Prostate Cancer and Prostatic Diseases - Contemporary management of men with high-risk localized prostate cancer in the United States
• Prostate Cancer and Prostatic Diseases - ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer[mdash]results from an international multicenter study
• Faced with life-threatening diseases, patients take over - The San Diego Union-Tribune  
• The Prostate Cancer Foundation, in Collaboration With World’s Leading Researchers, Publish Standard
• 2017 Patient Guide - PCF 

Life Choices

can influence the odds in your favor:

• Statins Tied to Lower Death Risk in Prostate Cancer | Medpage Today
• Prostate Cancer Prevention: 12 Ways to Protect Your Prostate
• Pre-surgical weight loss in the surgical treatment of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK 
• Shift-work, night-work, and risk for prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK

Diet

can starve the cancer

• Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study - The Journal of Urology  
• New Data on High Dose Vitamin C Therapy and Prostate Cancer
• Science Weighs in On How Fat Raises Cancer Risk | Cooking with Kathy Man  
•  

Exercise

can give you strength to fight the cancer and treatment side effects

• Nutrients | Free Full-Text | The Effect of Nutrition Therapy and Exercise on Cancer-Related Fatigue and Quality of Life in Men with Prostate Cancer: A Systematic Review 

Screening and Diagnosis

early detection is important because symptoms appear too late for treatment:

• spendergast: September is Prostate Cancer Awareness Month
• Father-adult son communication about prostate cancer and prostate cancer risk | THE "NEW" PROSTATE CANCER INFOLINK   
• Leveraging the Family Influence of Women in Prostate Cancer Efforts Targeting African American Men.
• Setback in prostate cancer battle? - The San Diego Union-Tribune 
• The latest federal guidelines on prostate cancer screenings are important | TheHill
• New Study Offers Support for Prostate Testing - The New York Times
• (3) How do physicians learn to do prostate exams? - Quora 

Biopsies and Pathology

• Risk stratification in oligometastatic prostate cancer: where are we and what do we need?
• Access : Multiparametric MRI|[sol]|ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men : Prostate Cancer and Prostatic Diseases
• Prostate Cancer and Prostatic Diseases - Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed[quest] 
• Access : Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach : Prostate Cancer and Prostatic Diseases
• Where Do TRUS- and MRI Guided Biopsies Miss Significant Prostate Cancer? - Urology 

Genomics

• Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017 — BioPortfolio.com   
• AMBIGUITY IN A MASCULINE WORLD: Being a BRCA1/2 mutation carrier and a man with prostate cancer - Moynihan - 2017 - Psycho-Oncology - Wiley Online Library

Tests

• Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer | Cancer Research   
• Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer - Pedraza-Arévalo - 2017 - The Prostate - Wiley Online Library

Imaging

• High Resolution PET-MRI Before Prostate Cancer HIFU   
• Diagnostics | Free Full-Text | Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer
• Association between pathology and texture features of multi parametric MRI of the prostate - IOPscience 
• New imaging technique spots prostate tumors starved of oxygen -- ScienceDaily
• A Combined Learning Algorithm for Prostate Segmentation on 3D CT Images - Ma - 2017 - Medical Physics - Wiley Online Library  
• PI-RADSv2 For Staging Prostate Cancer | Diagnostic Imaging
• Co-trained convolutional neural networks for automated detection of prostate cancer in multi-parametric MRI - Medical Image Analysis  
• Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

Treatment

• Decision aids and decision-making in prostate cancer risk | THE "NEW" PROSTATE CANCER INFOLINK 
• Alternative medicine in the treatment of cancer (prostate cancer included) | THE "NEW" PROSTATE CANCER INFOLINK  
• Alternative Medicine Alone as Cancer Treatment Increases Risk of Dying Early | Cooking with Kathy Man 

Active Surveillance AS

• Prostate Cancer and Prostatic Diseases - Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance[quest]   
• Prostate Cancer and Prostatic Diseases - Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project
• Prostate Cancer and Prostatic Diseases - Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance  
• Variation in the use of active surveillance for low-risk prostate cancer - Löppenberg - 2017 - Cancer - Wiley Online Library

Surgery RP

frequently the first choice for localized PCa, robotic assist dominates:

• Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases? - Jang - 2017 - BJU International - Wiley Online Library   
• Predischarge Predictors of Readmissions and Postdischarge Complications in Robot-Assisted Radical Prostatectomy | Abstract
• Pre-surgical weight loss in the surgical treatment of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK 

Radiation RT

• Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy: Acta Oncologica: Vol 0, No 0   
• Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
• Access : Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database : Prostate Cancer and Prostatic Diseases  
• Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity
• Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy - Tsumura - 2017 - The Prostate - Wiley Online Library 

Hormone ADT

• Kaiser Permanente Release Androgen Deprivation Therapy Associated With Higher Risk Of Heart Failure In Men With Early Stage Prostate Cancer 
• Androgen Deprivation Therapy Associated With Increased Risk Of Cardiovascular Disease — BioPortfolio.com   
• Combination hormonal therapy boosts survival in men with aggressive prostate cancer - Harvard Health Blog - Harvard Health Publications
• Coming soon? A new formulation of abiraterone acetate? | THE "NEW" PROSTATE CANCER INFOLINK 
• Study: There Is a Free Lunch (for Prostate Cancer Docs)
• Chaarting direction after stampeding along the relevant latitude | THE "NEW" PROSTATE CANCER INFOLINK 
• Common Treatment for Early Prostate Cancer May Carry Heart Risk - Drugs.com MedNews
• ADT and risk for cardiovascular complications of therapy | THE "NEW" PROSTATE CANCER INFOLINK 
• Prostate Cancer ADT Linked With Cardiovascular Risks, Depression - Renal and Urology News
• ADT Ups Risk for Heart Failure in Men With Prostate Cancer  
• Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies: Cancer Cell

Chemo

•  Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post STAMPEDE world - Thompson - 2017 - BJU International - Wiley Online Library 
• Prostate cancer: Localized docetaxel delivery is feasible : Nature Reviews Urology : Nature Research 
• Chemotherapy for oligometastatic prostate cancer
• Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer | Cancer Research 

Immunotherapy

• Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer — BioPortfolio.com   
• Scientists develop novel immunotherapy technology for prostate cancer: This gene-based delivery system can instruct the body to generate therapeutic antibodies against cancer cells -- ScienceDaily

New Techniques

• Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study - Struss - 2017 - The Prostate - Wiley Online Library 

Side Effects

• Hormone Treatment for Prostate Cancer Tied to Heart Risks - The New York Times
• Common Treatment for Early Prostate Cancer May Carry Heart Risk: MedlinePlus Health News   
• Common Treatment for Early Prostate Cancer May Carry Heart Risk | Cooking with Kathy Man
• Risk of Alzheimer’s Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer: Journal of Clinical Oncology: Vol 0, No 0 
• Prostate Cancer Patients Improve Bone Health with Osteoporosis Drugs by Dr David Samadi
• Access : Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis : Prostate Cancer and Prostatic Diseases  
• September: Erectile Dysfunction After Prostate Cancer
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer | Annals of Internal Medicine | American College of Physicians  
• Maintaining Bone Health During Hormonal Therapy for Prostate Cancer | Annals of Internal Medicine | American College of Physicians

Advanced/Recurrence

• One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ - Full Text View - ClinicalTrials.gov   
• Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer: Journal of Clinical Oncology: Vol 0, No 0
• Access : Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases : Prostate Cancer and Prostatic Diseases 
• Access : Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis : Prostate Cancer and Prostatic Diseases
• Risk factors for metastatic prostate cancer: A sentinel event case series - Paller - 2017 - The Prostate - Wiley Online Library 
• Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology

September is Prostate Cancer Awareness Month

Prostate cancer The American Cancer Society recommends that men make an informed decision with their doctor about whether to be tested for prostate cancer. Research has not yet proven that the potential benefits of testing outweigh the harms of testing and treatment. The American Cancer Society believes that men should not be tested without learning about what we know and don’t know about the risks and possible benefits of testing and treatment. Starting at age 50, men should talk to a doctor about the pros and cons of testing so they can decide if testing is the right choice for them. If they are African American or have a father or brother who had prostate cancer before age 65, men should have this talk with a doctor starting at age 45. If men decide to be tested, they should have the PSA blood test with or without a rectal exam. How often they are tested will depend on their PSA level. http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer Statement from President Donald J. Trump on National Prostate Cancer Awareness Month | whitehouse.gov in fighting prostate cancer, we are still mindful that it remains the second leading cause of cancer deaths among men.  My Administration remains dedicated to finding better diagnostic and treatment options through the 21st Century Cures Act, as well as research collaborations between the Department of Health and Human Services, private industry, and the academic community.  In addition, the National Institutes of Health is investing in research that will improve upon current approaches to combatting prostate cancer.  Through these efforts and others, American men can experience a healthier future. This month, I encourage men to talk with their healthcare providers about their risk for prostate cancer.  I also call upon all Americans to do their part in raising awareness of this disease.  We pray for Americans currently fighting prostate cancer and recognize the progress yet to be made in finding its cure.  San Diego Community News Group - Events set to highlight Prostate Awareness Month  Texting“4Cure” to 20222 is the easiest thing you can to show your support for Prostate Awareness Month, also known as “Blue September.”  What is “Blue September?” September is Prostate Cancer Awareness Month, also referred to as “Blue September.” First conceptualized in New Zealand in 2008, Blue September expanded to Australia in its second year. This year, thanks to some local efforts, the campaign has evolved into an international awareness and fundraising initiative. San Diego radio personality Steve West of 91X helped launch the campaign here in San Diego with a 40-hour, non-stop resurrection marathon over Labor Day weekend, raising money for preventative research to help find a cure for this highly-curable cancer. West was diagnosed with prostate cancer in July 2004 and — because of early detection — was able to beat it. Actually, West’s discovery of his prostate cancer happened quite accidentally. He went to his doctor because he was having extreme migraines. “Apparently, my head that is always up my ass knew there was a problem!” West joked. While there, his doctor mentioned that West had never had a prostate-specific antigen (PSA) test — a primary tool to used to identify possible prostate cancer. “Because of the test, I am here today,” West said Read more: San Diego Community News Group - Events set to highlight Prostate Awareness Month   September Is National Prostate Cancer Awareness Month - As the month of September brings prostate cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated prostate cancer information throughout the year. Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer death in men, second only to lung cancer. According to American Cancer Society, there will be an estimated 192,280 new cases of prostate cancer and an estimated 27,360 deaths in the United States during 2009.[1] Staying informed with the latest news on prevention and screening is an important step in reducing your risk of developing prostate cancer. And, should a diagnosis occur, access to current, in-depth treatment information can help you find the best care. Learning More About Prostate Cancer Find great tips on recognizing early symptoms of prostate cancer and insight into management of the disease at http://www.cancerconsultants.com/cancer-tips/. To find expanded information on the prevention, screening, and treatment of prostate cancer, and stay updated with the lasted news on the disease, visit the Prostate Cancer Information Center. Sign up to receive Cancer Consultants’ free online prostate cancer newsletter, which provides disease-specific features, current news, tips, and nutrition and wellness information. Subscribe at http://www.cancerconsultants.com/about-cancerconsultants/subscription/. Visit the Cancer Store on Cancerconsultants.com for books whose topics range from personal cancer memoirs to expert nutritional guides about fueling your body to prevent and fight cancer. Let’s make it “Prostate Cancer Education Month”.   If you’re already aware - we’d like to help you with your journey. To accomplish that we are doing a series of webinars on the first 3 Wednesdays of September, called Webinar Wednesdays. (we will do the same in Oct, Nov, and Dec – stay tuned). Jan Manarite The first Webinar Wednesday is this Wed, Sept 6th from 2:00 – 3:00 pm Eastern Time. Led and moderated by Jan Manarite. Intended Audience: Men who are Newly Diagnosed with prostate cancer, or their wives or partners. Goal: To help you understand your medical records and Risk Category.  Every prostate cancer is different - do you understand yours?  It will help with your research, questions, and decisions. Pre-Registration Required. For questions or to register, email Jan - JManarite@hotmail.com      -------------------------------------------------------------------------------------------- The second Webinar Wednesday is Wed, Sept 13th from 2:00 – 3:00 pm Eastern Time. Intended Audience:  Men who are on Active Surveillance, or considering Active Surveillance. Goal:  Have some meaningful discussion about other men's experiences - successes or failures.  How do they 'surveil' their prostate cancer?  What tips do they have for you. Led and moderated by Mike Scott.  There will be several experienced AS patients on the call - learn from them. Pre-Registration Required:  For questions or to register, email Jan - JManarite@hotmail.com ---------------------------------------------------------------------------- The third Webinar Wednesday is Wed, Sept 20th from 2:00 – 3:30 pm Eastern Time. Intended Audience:     Ideally for patients (and their partners), who are planning to start ADT in the near future OR Ideally for patients currently on ADT, and their partners, concerned about ADT side effects. Goal:  Learn about solutions for side effects, and promote understanding between patients and partners as they experience the ADT journey together. Presented by author and PC patient Richard Wassersug, PhD.  Moderated by Jan Manarite Step Up For Blue – September is Prostate Cancer Awareness Month  . Purchase of book, Androgen Deprivation Therapy highly recommended. Pre-Registration Required:  For questions or to register, email Jan - JManarite@hotmail.com ---------------------------------------------------------- Visit The "New" Prostate Cancer InfoLink Social Network at: http://prostatecancerinfolink.ning.com/?xg_source=msg_mes_network To control which emails you receive on The "New" Prostate Cancer InfoLink Social Network, click here